Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 30:29:1611033.
doi: 10.3389/pore.2023.1611033. eCollection 2023.

CircRNA: A new class of targets for gastric cancer drug resistance therapy

Ying Zheng  1   2   3 , Zhe Li  2   3 , Yao Wang  1   2   3 , Wanjiao Chen  2 , Yifan Lin  2   3 , Junming Guo  1   2   3 , Guoliang Ye  2   3
Affiliations
Review

CircRNA: A new class of targets for gastric cancer drug resistance therapy

Ying Zheng et al. Pathol Oncol Res. .

Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide. Patients with advanced GC need palliative care to ensure survival. This includes the use of chemotherapy agents, such as cisplatin, 5-fluorouracil, oxaliplatin, paclitaxel, and pemetrexed, as well as targeted agents. However, the emergence of drug resistance evidence in poor patient outcomes and poor prognosis is a motivation to determine the specific mechanism of drug resistance. Interestingly, circular RNAs (circRNAs) play an important part in the carcinogenesis and progression of GC and are involved in GC drug resistance. This review systematically summarizes the functions and mechanisms of circRNAs underlying GC drug resistance, especially chemoresistance. It also emphasizes that circRNAs can serve as promising targets for improving drug resistance and therapeutic efficacy.

Keywords: biogenesis; circular RNA; drug resistance; gastric cancer; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
CircRNAs in GC. CircRNAs play a vital role in drug resistance by interacting with miRNAs and mRNAs, circRNAs, circular RNAs; miRNAs, microRNAs; mRNAs, and messenger RNAs.
FIGURE 2
FIGURE 2
Biogenesis and functions of circRNAs. (A) RBP and ALU-mediated circRNA generation. (B) Mechanism of intronic circRNA generation. (C) Lariat-driven mediated circRNA generation. (D) Function as miRNA sponge. (E) Interaction with RBPs. (F) Translation into proteins or polypeptides. (G) Enhancer of gene expression.
FIGURE 3
FIGURE 3
CircRNAs mediate the mechanism of drug resistance in GC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Lu T, Sun L, Zhu X. Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells. Biomed Pharmacother (2018) 105:1269–75. 10.1016/j.biopha.2018.06.031 - DOI - PubMed
    1. McDonald J, Swami N, Hannon B, Lo C, Pope A, Oza A, et al. Impact of early palliative care on caregivers of patients with advanced cancer: Cluster randomised trial. Ann Oncol (2017) 28:163–8. 10.1093/annonc/mdw438 - DOI - PubMed
    1. Japanese Gastric Cancer Treatment Guidelines 2021. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer (2023) 26:1–25. 10.1007/s10120-022-01331-8 - DOI - PMC - PubMed
    1. Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, et al. Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: A propensity score-matched analysis. JAMA Oncol (2018) 4:31–8. 10.1001/jamaoncol.2017.2805 - DOI - PMC - PubMed

MeSH terms